Chemosensitisation of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor

By Hellawell G.   Ferguson D.   Brewster S.   Macaulay V.  

European Urology Supplements, Vol. 2, Iss. 1, 2003-02 ,pp. : 36-36

Elsevier

Access to resources Recommend Favorite

Insulin-like growth factor I and prostate cancer

By O'Brien M.F.   Watson R.W.G.   Fitzpatrick J.M.  

Urology, Vol. 58, Iss. 1, 2001-07 ,pp. : 1-7

Elsevier

Access to resources Recommend Favorite

Insulin-like Growth Factor I Receptor Antagonism Augments Response to Chemoradiation Therapy in Colon Cancer Cells

By Perer E.S.   Madan A.K.   Shurin A.   Zakris E.   Romeguera K.   Pang Y.   Beech D.J.  

Journal of Surgical Research, Vol. 94, Iss. 1, 2000-11 ,pp. : 1-5

Academic Press

Access to resources Recommend Favorite

Racial differences in insulin-like growth factor binding protein-3 in men at increased risk of prostate cancer

By Tricoli J.V.   Winter D.L.   Hanlon A.L.   Raysor S.L.   Watkins-Bruner D.   Pinover W.H.   Hanks G.E.  

Urology, Vol. 54, Iss. 1, 1999-07 ,pp. : 178-182

Elsevier

Access to resources Recommend Favorite

Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection

By Djavan B.   Bursa B.   Seitz C.   Soeregi G.   Remzi M.   Basharkhah A.   Wolfram R.   Marberger M.  

Urology, Vol. 54, Iss. 4, 1999-10 ,pp. : 603-606

Elsevier

Access to resources Recommend Favorite